COGNICURRENT

Jan 5 • 03:00 UTC • 🇨🇳 China • South China Morning Post

The ‘biology winter’ thaws: why investors are piling into Hong Kong’s biotech IPOs

Investors are increasingly supporting biotech IPOs in Hong Kong due to a resurgence in licensing deals and positive post-IPO performance, driving expectations of continued momentum through 2026.

#biotech #hong kong #ipo #investors #pharmaceuticals

Read Original Back to Feed

📡 Similar Coverage

🇨🇳 China Feb 28 • 02:00 UTC

The big cornerstone comeback: what’s driving investors back to Hong Kong IPOs?

South China Morning Post

🇨🇳 China Mar 5 • 10:59 UTC

China and Hong Kong should relax biotech listing rules, venture capitalist says

South China Morning Post

🇨🇳 China Feb 10 • 05:00 UTC

Chinese investors pour into Hong Kong-listed drug stocks as international deals multiply

South China Morning Post

🇨🇳 China Mar 17 • 23:30 UTC

Chinese banks outpace rivals in Hong Kong wealth growth on IPO boom, capital flows

South China Morning Post

🇨🇳 China Jan 1 • 08:37 UTC

Why investors should remain bullish on Hong Kong, mainland stocks in 2026

South China Morning Post

🇨🇳 China Mar 1 • 04:00 UTC

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, licensing deals

South China Morning Post